What Happened to Peptide Sciences?

Peptide Sciences was not a marginal player. They served an estimated one million monthly users — researchers, licensed practitioners, and institutions that built their sourcing around the company's catalog and purity standards. When they went dark, those users needed answers. This page provides them.

Section 1

The Timeline

Peptide Sciences did not collapse overnight. Three distinct forces converged over 18 months, creating legal, regulatory, and operational pressure that the company ultimately could not absorb simultaneously.

2014 – 2025

Peptide Sciences operates as the dominant U.S. research peptide supplier for over a decade — building a broad catalog, a large customer base, and a reputation for consistent product availability.

2024 – 2025

The FDA significantly escalates enforcement against research peptide suppliers, issuing 50+ warning letters across the sector. The industry environment shifts materially — companies with unclear compliance postures become exposed.

June 2025

Amino Asylum is raided by federal agents — the most visible enforcement action against a research peptide supplier to that point. The raid signals that enforcement is no longer theoretical.

Late 2025

Independent Janoshik testing reveals purity failures on Peptide Sciences product batches, including counterfeit detections on retatrutide. The findings circulate widely in research communities and compound reputational damage precisely when regulatory scrutiny is highest.

March 6, 2026

Peptide Sciences voluntarily ceases operations. The company does not announce a wind-down timeline or asset transfer. Orders stop processing. The site goes dark.

The Three Converging Forces

GLP-1 Pharmaceutical Litigation

Eli Lilly and Novo Nordisk applied sustained legal pressure on research peptide suppliers carrying Semaglutide and Tirzepatide — the same compounds at the center of a $50B+ branded pharmaceutical market. Suppliers carrying these compounds became primary litigation targets.

FDA Enforcement Escalation

The FDA sent 50+ warning letters to peptide suppliers in 2024–2025. The Amino Asylum raid in June 2025 demonstrated willingness to escalate beyond letters. Passage of the SAFE Drugs Act (H.R.6509) added further legislative pressure on the research compound sector.

Quality Failures & Payment Fragility

Independent Janoshik testing revealed purity failures including counterfeit detections on Peptide Sciences retatrutide batches — damaging consumer trust at the worst possible moment. Simultaneously, high-risk merchant accounts across the sector were being terminated, disrupting payment infrastructure industry-wide.

The Peptide Sciences closure was not the result of any single regulatory action. It was the convergence of sustained pharmaceutical litigation, escalating federal enforcement, and documented quality failures — three pressure vectors that arrived simultaneously during a period of industrywide merchant account fragility.

The market's lesson is clear: quality infrastructure, regulatory positioning, and entity structure matter more now than at any prior point in the research peptide market's history.

Section 2

What This Means for Researchers

Peptide Sciences served an enormous segment of the qualified researcher and licensed practitioner market. Their exit creates a sourcing gap that demands a considered response — not a hasty one.

Largest Supplier Migration in Market History

The vacuum left by Peptide Sciences represents the largest single-supplier migration event the research peptide market has experienced. Thousands of researchers and licensed practitioners are now re-evaluating their sourcing relationships simultaneously.

Standards Must Go Up, Not Down

The market has watched what happens when quality verification is inadequate and regulatory positioning is weak. Researchers migrating to a new supplier should demand third-party COAs, independent lab verification, and a clear entity structure — not just availability and price.

The RUO Framework Remains Intact

The Peptide Sciences closure was company-specific — it was not a ruling on the legality of the research peptide market. Research-grade compounds under the RUO (Research Use Only) framework remain available to licensed professionals and qualified researchers. The regulatory risk is supplier-specific, not categorical.

Section 3

What Sequence Labs Offers

PA-C and DEA-registered practitioner review — every product in the Sequence Labs catalog is reviewed by a licensed PA-C and a DEA-registered practitioner. Not a marketing claim — a structural quality control layer.

Krause Analytical (Austin, TX) COAs — batch-specific certificates of analysis from a named, independent laboratory. Publicly accessible and independently verifiable via Finnrick Pulse. No self-reported purity claims.

Montana LLC structure — entity domicile chosen for regulatory stability. Not a shelf company or a post-office-box operation. Structural decisions made before product decisions.

Competitive pricing — structured to undercut the remaining market. Lower price does not mean lower quality; it means deliberate margin decisions made in favor of researcher access and long-term volume relationships.

Full Catalog — 20+ Compounds

Semaglutide Tirzepatide Retatrutide BPC-157 TB-500 NAD+ CJC-1295 Ipamorelin Sermorelin Tesamorelin GHK-Cu Epithalon MOTS-c SS-31 Semax Selank PT-141 KPV AICAR + More

Wholesale / B2B Program: Sequence Labs offers tiered wholesale pricing for licensed practitioners, medical spas, and research institutions. No monthly commitments. Tiers scale with per-order volume. Contact Team@SequenceLabs.Health or use the Partner With Us form to apply.

View Full Catalog Partner With Us

Section 4

Frequently Asked Questions

Is it legal to buy research peptides after Peptide Sciences closed?

Research-grade peptides for licensed professionals and qualified researchers remain legal under the RUO (Research Use Only) framework. The Peptide Sciences closure was company-specific — not a blanket prohibition on the research peptide market. Researchers should evaluate suppliers on compliance posture, quality verification, and entity structure — not simply on availability.

Where can I find Peptide Sciences' former products?

Sequence Labs carries the full range of compounds previously available from Peptide Sciences, including GLP-1 agonists (Semaglutide, Tirzepatide, Retatrutide) and peptide repair compounds (BPC-157, TB-500, GHK-Cu). View the full catalog at sequencelabs.health/products.html.

How do I know Sequence Labs' products are authentic?

Every Sequence Labs product is tested by Krause Analytical (Austin, TX) with batch-specific COAs publicly available and independently verifiable via Finnrick Pulse. Unlike self-reported purity claims, our COAs are third-party verified and lot-linked. You can cross-reference any batch certificate against the Finnrick Pulse database before placing an order.

Does Sequence Labs offer the same wholesale pricing as Peptide Sciences?

Yes — we offer B2B wholesale tier pricing for licensed practitioners, medical spas, and research institutions. Tiers are based on per-order volume with no monthly commitments. Contact Team@SequenceLabs.Health or use the Partner With Us form to apply.

Sequence Labs

Browse the Sequence Labs catalog —
COA-backed, PA-C reviewed, Montana LLC

The research peptide market has changed. Sequence Labs was built for exactly this moment — rigorous quality verification, transparent pricing, and the regulatory positioning to remain operational.